Search Result

Results for "

GlyT

" in MedChemExpress (MCE) Product Catalog:

By Targets:	GlyT (33) 5-HT Receptor (2) Deubiquitinase (1) Endogenous Metabolite (8) GPR55 (1) iGluR (1) Isotope-Labeled Compounds (3) P2X Receptor (2)
By Research Areas:	Cancer (4) Cardiovascular Disease (1) Inflammation/Immunology (2) Metabolic Disease (4) Neurological Disease (26)

Inhibitors & Agonists

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Targets Recommended: GlyT

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-112432

GlyT1 Inhibitor 1	GlyT	Neurological Disease
GlyT1 Inhibitor 1 is a potent and selective *GlyT1* inhibitor with an IC₅₀ of 38 nM for rGlyT1 . Antipsychotic activity .

HY-111029A

ALX-1393 TFA	GlyT	Others
ALX-1393 TFA, a selective *GlyT2* inhibitor, has an antinociceptive effect on thermal, mechanical, and chemical stimulations in a rat acute pain model .

HY-138935

Iclepertin 1 Publications Verification BI-425809	GlyT	Neurological Disease
Iclepertin (BI-425809) is a potent, selective and orally active glycine transporter 1 (GlyT1) inhibitor. Iclepertin is inactive against GlyT2. Iclepertin can be used for Alzheimer disease and schizophrenia research .

HY-10809

Bitopertin 1 Publications Verification RG1678; RO4917838	GlyT	Neurological Disease
Bitopertin is a potent, noncompetitive glycine reuptake inhibitor, inhibits glycine uptake at human *GlyT1* with a concentration exhibiting IC50 of 25 nM.

HY-100416A

LY2365109 hydrochloride	GlyT	Neurological Disease
LY2365109 hydrochloride is a potent and selective *GlyT1* inhibitor, with an IC₅₀ of 15.8 nM for glycine uptake in cells over-expressing hGlyT1a .

HY-14568

DCCCyB	GlyT	Neurological Disease
DCCCyB is an orally bioavailable, potent, and selective inhibitor of *GlyT1. DCCCyB demonstrates excellent in vivo occupancy of GlyT*1 transporters in rhesus monkey .

HY-10712

Org-24598	GlyT	Neurological Disease
Org-24598 is an inhibitor of glycine transporter 1 GlyT-1 . Org-24598 can inhibit the specific binding of [ ³H] CHIBIA-3007 to the rat brain membranes with a Ki value of 16.9 nM .

HY-10713

Org-24598 lithium	GlyT	Neurological Disease
Org-24598 lithium is an inhibitor of glycine transporter 1 GlyT-1 . Org-24598 lithium can inhibit the specific binding of [ ³H] CHIBIA-3007 to the rat brain membranes with a Ki value of 16.9 nM .

HY-19887

Tilapertin AMG747	GlyT	Neurological Disease
Tilapertin is an oral inhibitor of glycine transporter type-1 (GlyT1).

HY-113261A

(Rac)-Oleoylcarnitine	Others	Neurological Disease
(Rac)-Oleoylcarnitine is an endogenous acylcarnitine and a potential noncompetitive inhibitor of glycine transporter 2 (GLYT2) that can be used as a pain suppressant.

HY-111029

ALX-1393	GlyT	Neurological Disease
ALX-1393, a selective *GlyT2* inhibitor, has an antinociceptive effect on thermal, mechanical, and chemical stimulations in a rat acute pain model .

HY-100416

LY2365109	GlyT	Neurological Disease
LY2365109 is a potent and selective *GlyT1* inhibitor, with an IC₅₀ of 15.8 nM for glycine uptake in cells over-expressing hGlyT1a .

HY-113202S1

Stearoyl-L-carnitine-d9 chloride	Isotope-Labeled Compounds GlyT	Metabolic Disease
Stearoyl-L-carnitine-d9 chloride is the deuterium labeled Stearoyl-L-carnitine chloride. Stearoyl-L-carnitine chloride is an endogenous long-chain acylcarnitine. Stearoyl-L-carnitine chloride is a less potent inhibitor of GlyT2 .

HY-10809A

Bitopertin (R enantiomer) RG1678 (R enantiomer); RO4917838 (R enantiomer)	GlyT	Neurological Disease
Bitopertin R enantiomer (RG1678 R enantiomer; RO4917838 R enantiomer) is the R-enantiomer of Bitopertin. Bitopertin is a potent, noncompetitive glycine reuptake inhibitor, inhibits glycine uptake at human *GlyT1* with a concentration exhibiting IC50 of 25 nM.

HY-130466

Stearoyl-L-carnitine chloride 1 Publications Verification	Endogenous Metabolite GlyT	Metabolic Disease
Stearoyl-L-carnitine chloride is an endogenous long-chain acylcarnitine. Stearoyl-L-carnitine chloride is a less potent inhibitor of *GlyT2*. Stearoyl-L-carnitine chloride inhibits glycine responses by 16.8% at concentrations up 3 μM .

HY-10716A

PF-03463275	GlyT	Neurological Disease
PF-03463275 is a centrally penetrant, orally available, selective, and competitive *GlyT1* (glycine transporter-1) reversible inhibitor, with a K_i of 11.6 nM. PF-03463275 has the potential for Schizophrenia research .

HY-10716

PF-03463275 hydrochloride	GlyT	Neurological Disease
PF-03463275 hydrochloride is a centrally penetrant, orally available, selective, and competitive *GlyT1* (glycine transporter-1) reversible inhibitor, with a K_i of 11.6 nM. PF-03463275 hydrochloride has the potential for Schizophrenia research .

HY-110176

ASP2535	GlyT	Neurological Disease
ASP2535 is a potent, orally bioavailable, selective, brain permeable and centrally-active glycine transporter-1 (GlyT1) inhibitor. ASP2535 can improve cognitive impairment in animal models of schizophrenia and Alzheimer's disease .

HY-107527

Org 25543 hydrochloride	GlyT	Neurological Disease
Org 25543 hydrochloride is a selective and irreversible *GlyT2* inhibitor (IC₅₀: 16 nM). Org 25543 hydrochloride has analgesia effect. Org 25543 hydrochloride ameliorates mechanical allodynia after partial sciatic nerve ligation injury in mice .

HY-10715

SSR504734	GlyT	Neurological Disease
SSR504734 is an orally active, selective and reversible inhibitor of human, rat, and mouse *GlyT1* (IC₅₀=18, 15, and 38 nM, respectively). SSR504734 shows anti-schizophrenia, anti-anxiety and anti-depression activities .

HY-10711A

ALX-5407 hydrochloride (R)-NFPS hydrochloride	GlyT	Neurological Disease
ALX-5407 ((R)-NFPS) hydrochloride is a selective and orally active glycine transporter *GlyT1* inhibitor with an IC₅₀ value of 3 nM. ALX-5407 hydrochloride can be used the research of N-methyl-D-aspartate-receptor function and schizophrenia .

HY-148708

Oleoyl-D-lysine	iGluR	Neurological Disease
Oleoyl-D-lysine is a selective Glycine Transporter-2 (GlyT2) inhibitor based on lipid. Oleoyl-D-lysine reverses neuropathic pain in mice, shows antidrowsiness effect on chronic neuropathic pain. Oleoyl-D-lysine is safe and effective without respiratory depression .

HY-114895

SSR504734 free base	GlyT	Neurological Disease
SSR504734 free base is an orally active, selective and reversible inhibitor of human, rat, and mouse *GlyT1* (IC₅₀=18, 15, and 38?nM, respectively). SSR504734 free base shows anti-schizophrenia, anti-anxiety and anti-depression activities .

HY-130466S

Stearoyl-L-carnitine-d3 chloride	Endogenous Metabolite GlyT	Metabolic Disease
Stearoyl-L-carnitine-d₃ (chloride) is the deuterium labeled Stearoyl-L-carnitine chloride. Stearoyl-L-carnitine chloride is an endogenous long-chain acylcarnitine. Stearoyl-L-carnitine chloride is a less potent inhibitor of GlyT2. Stearoyl-L-carnitine chloride inhibits glycine responses by 16.8% at concentrations up 3 μM[1][2].

HY-111162

GSK494581A	GPR55 GlyT	Cardiovascular Disease Neurological Disease
GSK494581A is a specific ligand for human GPR55 (pEC₅₀ of 6.8) and also acts as an inhibitor of glycine transporter subtype 1 (GlyT1). GSK494581A may regulate pain signaling, bone morphogenesis, and vascular endothelial cell formation by binding to GPR55 .

HY-101037

Sarcosine 1 Publications Verification N-Methylglycine; Sarcosin	Endogenous Metabolite GlyT	Cancer
Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia .

HY-122666

Org 25935	GlyT	Metabolic Disease
Org 25935 is a potent and selective glycine transporter 1 protein (GlyT1) inhibitor with an IC₅₀ value of 100 nM. Org 25935 can decrease ethanol (EtOH) intake and EtOH preference in rats, whereas water intake is unaffected. Org 25935 can be used for researching alcohol dependence or abuse .

HY-107526

(Rac)-ALX 5407 (Rac)-NFPS	GlyT	Neurological Disease
NFPS is a selective, non-competitive glycine transporter-1 (GlyT1) inhibitor with IC₅₀s of 2.8 nM and 9.8 nM for hGlyT1 and rGlyT1, respectively . NFPS exerts neuroprotection via glyR alpha1 subunit in the rat model of transient focal cerebral ischaemia and reperfusion .

HY-18638

TCID 2 Publications Verification 4,5,6,7-Tetrachloroindan-1,3-dione	Deubiquitinase	Neurological Disease
TCID (4,5,6,7-Tetrachloroindan-1,3-dione) is a potent and selective neuronal ubiquitin C-terminal hydrolase (UCH-L3) inhibitor with an IC₅₀ of 0.6 μM . TCID diminishes glycine transporter GlyT2 ubiquitination in brainstem and spinal cord primary neurons .

HY-101037S1

Sarcosine-d3 N-Methylglycine-d₃; Sarcosin-d₃	Isotope-Labeled Compounds Endogenous Metabolite GlyT	Cancer
Sarcosine-d₃ is the deuterium labeled Sarcosine. Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia[1][2].

HY-111189

GSK931145	Others	Neurological Disease
GSK931145 is a glycine transporter 1 (GlyT1) inhibitor with anti-epileptic activity. GSK931145 exhibits a low minimum effective dose in the maximum electrical stimulation threshold test, indicating that it has a significant anti-epileptic effect. GSK931145 is also suitable as a positron emission tomography (PET) radioligand for quantifying the availability of glycine transporters in the living brain .

HY-103332

N-Arachidonylglycine 1 Publications Verification NA-Gly	GlyT Endogenous Metabolite	Inflammation/Immunology
N-Arachidonylglycine (NA-Gly), a carboxylic analog of the endocannabinoid anandamide (AEA), is a GPR18 agonist (EC₅₀ = 44.5 nM). Unlike AEA, N-Arachidonylglycine has no activity at either CB1 or CB2 receptors. N-Arachidonylglycine inhibits *GLYT2* (IC₅₀ = 5.1 μM). N-Arachidonylglycine also is an effective activator of endometrial cell migration .

HY-101037S

Sarcosine-15N N-Methylglycine-¹⁵N; Sarcosin-¹⁵N	Endogenous Metabolite GlyT	Cancer
Sarcosine- ¹⁵N is the ¹⁵N-labeled Sarcosine. Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia[1][2].

HY-101037R

Sarcosine (Standard)	Endogenous Metabolite GlyT	Cancer
Sarcosine (Standard) is the analytical standard of Sarcosine. This product is intended for research and analytical applications. Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia .

HY-109067

Opiranserin VVZ-149	GlyT 5-HT Receptor P2X Receptor	Neurological Disease
Opiranserin (VVZ-149), a non-opioid and non-NSAID analgesic candidate, is a dual antagonist of glycine transporter type 2 (GlyT2) and serotonin receptor 2A (5HT2A), with IC₅₀s of 0.86 and 1.3 μM, respectively. Opiranserin shows antagonistic activity on rP2X3 (IC₅₀=0.87 μM). Opiranserin is development as an injectable agent for the treatment of postoperative pain .

HY-109067A

Opiranserin hydrochloride VVZ-149 hydrochloride	GlyT 5-HT Receptor P2X Receptor	Neurological Disease
Opiranserin (VVZ-149) hydrochloride, a non-opioid and non-NSAID analgesic candidate, is a dual antagonist of glycine transporter type 2 (GlyT2) and serotonin receptor 2A (5HT2A), with IC₅₀s of 0.86 and 1.3 μM, respectively. Opiranserin hydrochloride shows antagonistic activity on rP2X3 (IC₅₀=0.87 μM). Opiranserin hydrochloride is development as an injectable agent for the treatment of postoperative pain .

HY-103332S

N-Arachidonylglycine-d8 NA-Gly-d₈	Isotope-Labeled Compounds Endogenous Metabolite GlyT	Inflammation/Immunology
N-Arachidonylglycine-d8 is a deuterated labeled N-Arachidonylglycine . N-Arachidonylglycine (NA-Gly), a carboxylic analog of the endocannabinoid anandamide (AEA), is a GPR18 agonist (EC₅₀ = 44.5 nM). Unlike AEA, N-Arachidonylglycine has no activity at either CB1 or CB2 receptors. N-Arachidonylglycine inhibits *GLYT2* (IC₅₀ = 5.1 μM). N-Arachidonylglycine also is an effective activator of endometrial cell migration .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-130466

Stearoyl-L-carnitine chloride 1 Publications Verification	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite GlyT
Stearoyl-L-carnitine chloride is an endogenous long-chain acylcarnitine. Stearoyl-L-carnitine chloride is a less potent inhibitor of *GlyT2*. Stearoyl-L-carnitine chloride inhibits glycine responses by 16.8% at concentrations up 3 μM .

HY-101037

Sarcosine 1 Publications Verification N-Methylglycine; Sarcosin	Structural Classification Human Gut Microbiota Metabolites Immune System Disorder Microorganisms Classification of Application Fields Source classification Disease markers Endocrine diseases Amino acids Endogenous metabolite Disease Research Fields Cancer	Endogenous Metabolite GlyT
Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia .

HY-103332

N-Arachidonylglycine 1 Publications Verification NA-Gly	Structural Classification Alkaloids Classification of Application Fields Other Alkaloids Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields	GlyT Endogenous Metabolite
N-Arachidonylglycine (NA-Gly), a carboxylic analog of the endocannabinoid anandamide (AEA), is a GPR18 agonist (EC₅₀ = 44.5 nM). Unlike AEA, N-Arachidonylglycine has no activity at either CB1 or CB2 receptors. N-Arachidonylglycine inhibits *GLYT2* (IC₅₀ = 5.1 μM). N-Arachidonylglycine also is an effective activator of endometrial cell migration .

HY-113261A

(Rac)-Oleoylcarnitine	Microorganisms Source classification	Others
(Rac)-Oleoylcarnitine is an endogenous acylcarnitine and a potential noncompetitive inhibitor of glycine transporter 2 (GLYT2) that can be used as a pain suppressant.

HY-101037R

Sarcosine (Standard)	Structural Classification Human Gut Microbiota Metabolites Immune System Disorder Microorganisms Source classification Disease markers Endocrine diseases Amino acids Endogenous metabolite	Endogenous Metabolite GlyT
Sarcosine (Standard) is the analytical standard of Sarcosine. This product is intended for research and analytical applications. Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia .

Cat. No.	Compare	Product Name	Species	Source

HY-P703211

	GlyT1 Protein, Human (HEK293, His, GFP) Sodium- and chloride-dependent glycine transporter 1; Solute carrier family 6 member 9; SLC6A9; Homo sapiens; Human; GlyT-1	Human	HEK293
	GlyT1 Protein, Human (HEK293, His, GFP) is the recombinant human-derived GlyT1, expressed by HEK293 , with His, GFP labeled tag. ,

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-130466S

Stearoyl-L-carnitine-d3 chloride
Stearoyl-L-carnitine-d₃ (chloride) is the deuterium labeled Stearoyl-L-carnitine chloride. Stearoyl-L-carnitine chloride is an endogenous long-chain acylcarnitine. Stearoyl-L-carnitine chloride is a less potent inhibitor of GlyT2. Stearoyl-L-carnitine chloride inhibits glycine responses by 16.8% at concentrations up 3 μM[1][2].

HY-101037S1

Sarcosine-d3
Sarcosine-d₃ is the deuterium labeled Sarcosine. Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia[1][2].

HY-101037S

Sarcosine-15N
Sarcosine- ¹⁵N is the ¹⁵N-labeled Sarcosine. Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia[1][2].

HY-113202S1

Stearoyl-L-carnitine-d9 chloride
Stearoyl-L-carnitine-d9 chloride is the deuterium labeled Stearoyl-L-carnitine chloride. Stearoyl-L-carnitine chloride is an endogenous long-chain acylcarnitine. Stearoyl-L-carnitine chloride is a less potent inhibitor of GlyT2 .

HY-103332S

N-Arachidonylglycine-d8

N-Arachidonylglycine-d8 is a deuterated labeled N-Arachidonylglycine . N-Arachidonylglycine (NA-Gly), a carboxylic analog of the endocannabinoid anandamide (AEA), is a GPR18 agonist (EC₅₀ = 44.5 nM). Unlike AEA, N-Arachidonylglycine has no activity at either CB1 or CB2 receptors. N-Arachidonylglycine inhibits GLYT2 (IC₅₀ = 5.1 μM). N-Arachidonylglycine also is an effective activator of endometrial cell migration .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P83191

	GlyT2 Antibody (YA2936) NET1; GlyT2; HKPX3; GlyT-2	WB	Human, Rat
	GlyT2 Antibody (YA2936) is a biotin-conjugated non-conjugated IgG antibody, targeting GlyT2, with a predicted molecular weight of 87 kDa (observed band size: 87 kDa). GlyT2 Antibody (YA2936) can be used for WB experiment in human, rat background.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks